158 related articles for article (PubMed ID: 35171350)
1. Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.
Jia J; Howard L; Liu Y; Starr MD; Brady JC; Niedzwiecki D; Strickler JH; Nixon AB
Cancer Chemother Pharmacol; 2022 Mar; 89(3):413-422. PubMed ID: 35171350
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.
Strickler JH; Rushing CN; Uronis HE; Morse MA; Niedzwiecki D; Blobe GC; Moyer AN; Bolch E; Webb R; Haley S; Hatch AJ; Altomare IP; Sherrill GB; Chang DZ; Wells JL; Hsu SD; Jia J; Zafar SY; Nixon AB; Hurwitz HI
Oncologist; 2021 Jun; 26(6):465-e917. PubMed ID: 33469991
[TBL] [Abstract][Full Text] [Related]
3. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
Powles T; Choueiri TK; Motzer RJ; Jonasch E; Pal S; Tannir NM; Signoretti S; Kaldate R; Scheffold C; Wang E; Aftab DT; Escudier B; George DJ
BMC Cancer; 2021 Aug; 21(1):904. PubMed ID: 34364385
[TBL] [Abstract][Full Text] [Related]
4. Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes.
Bekaii-Saab TS; Lach K; Hsu LI; Siadak M; Stecher M; Ward J; Beckerman R; Strickler JH
Oncologist; 2023 Oct; 28(10):885-893. PubMed ID: 37463037
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib.
Liu Y; Lyu J; Bell Burdett K; Sibley AB; Hatch AJ; Starr MD; Brady JC; Hammond K; Marmorino F; Rossini D; Goldberg RM; Falcone A; Cremolini C; Owzar K; Ivanova A; Moore DT; Lee MS; Sanoff HK; Innocenti F; Nixon AB
Mol Cancer Ther; 2020 Oct; 19(10):2146-2154. PubMed ID: 32747417
[TBL] [Abstract][Full Text] [Related]
6. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
Shitara K; Muro K; Watanabe J; Yamazaki K; Ohori H; Shiozawa M; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Mori I; Yamanaka K; Hihara M; Soeda J; Misumi T; Yamamoto K; Yamashita R; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
Nat Med; 2024 Mar; 30(3):730-739. PubMed ID: 38347302
[TBL] [Abstract][Full Text] [Related]
7. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
Tolaney SM; Ziehr DR; Guo H; Ng MR; Barry WT; Higgins MJ; Isakoff SJ; Brock JE; Ivanova EV; Paweletz CP; Demeo MK; Ramaiya NH; Overmoyer BA; Jain RK; Winer EP; Duda DG
Oncologist; 2017 Jan; 22(1):25-32. PubMed ID: 27789775
[TBL] [Abstract][Full Text] [Related]
8. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606
[TBL] [Abstract][Full Text] [Related]
9. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A
Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365
[TBL] [Abstract][Full Text] [Related]
10. The prognostic role of HIF-1α and NF-κB expression in RAS wild-type metastatic colorectal cancer: A Turkish Oncology Group (TOG) study.
Demirkıran A; Kılınç F; Koçak MZ; Demirkıran D; Korkmaz M; Eryılmaz MK; Araz M; Karaağaç M; Artaç M
J Cancer Res Clin Oncol; 2023 Aug; 149(10):6849-6856. PubMed ID: 36808300
[TBL] [Abstract][Full Text] [Related]
11. Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in
Stahler A; Hoppe B; Na IK; Keilholz L; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Goekkurt E; Kasper S; Kind AJ; Kurreck A; Alig AHS; Held S; Reinacher-Schick A; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
J Clin Oncol; 2023 Jun; 41(16):2975-2987. PubMed ID: 37018649
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
[TBL] [Abstract][Full Text] [Related]
13. Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma.
Rimassa L; Kelley RK; Meyer T; Ryoo BY; Merle P; Park JW; Blanc JF; Lim HY; Tran A; Chan YW; McAdam P; Wang E; Cheng AL; El-Khoueiry AB; Abou-Alfa GK
Liver Cancer; 2022 Jan; 11(1):38-47. PubMed ID: 35222506
[TBL] [Abstract][Full Text] [Related]
14. A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01).
Scott AJ; Basu Mallick A; Dotan E; Cohen SJ; Gold PJ; Hochster HS; Subramaniam S; Barzi A; Watts GS; Blatchford PJ; Messersmith WA
Cancer Res Commun; 2022 Oct; 2(10):1188-1196. PubMed ID: 36969746
[TBL] [Abstract][Full Text] [Related]
15. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
16. Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer.
Jia J; Morse MA; Nagy RJ; Lanman RB; Strickler JH
Front Oncol; 2018; 8():305. PubMed ID: 30211110
[No Abstract] [Full Text] [Related]
17. Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy.
Price T; Ang A; Boedigheimer M; Kim TW; Li J; Cascinu S; Ruff P; Satya Suresh A; Thomas A; Tjulandin S; Peeters M
Cancer Biol Ther; 2020 Oct; 21(10):891-898. PubMed ID: 33026965
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab.
Nixon AB; Liu Y; Yang Q; Luo B; Starr MD; Brady JC; Kelly WK; Beltran H; Morris MJ; George DJ; Armstrong AJ; Halabi S
Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38347114
[TBL] [Abstract][Full Text] [Related]
19. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
